Yongwu Shao

机构：Gilead Sciences (Canada), Gilead Sciences (United States), Gilead Sciences (Australia) · ORCID：0009-0009-5384-5131

发表论文 35 篇 · 总被引 396 次 · h-index 10

代表论文

• Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial (2021 · The Lancet HIV · 被引 91)
• Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial (2019 · The Lancet HIV · 被引 43)
• Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial (2022 · Transgender Health · 被引 13)
• Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen (2019 · AIDS · 被引 9)
• HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial (2024 · The Lancet HIV · 被引 7)
• Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation (2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 7)